These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 39076855)

  • 1. SGLT2 Inhibition in Heart Failure with Preserved Ejection Fraction - The New Frontier.
    Aguiar-Neves I; Santos-Ferreira D; Fontes-Carvalho R
    Rev Cardiovasc Med; 2023 Jan; 24(1):1. PubMed ID: 39076855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Impact of SGLT2 Inhibitors on Cardiovascular Outcomes in Patients With Heart Failure With Preserved Ejection Fraction.
    Starr JA; Pinner NA
    Ann Pharmacother; 2024 May; 58(5):506-513. PubMed ID: 37542422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is it time for class I recommendation for sodium-glucose cotransporter-2 inhibitors in heart failure with mildly reduced or preserved ejection fraction?: An updated systematic review and meta-analysis.
    Treewaree S; Kulthamrongsri N; Owattanapanich W; Krittayaphong R
    Front Cardiovasc Med; 2023; 10():1046194. PubMed ID: 36824458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging Horizons in Heart Failure with Preserved Ejection Fraction: The Role of SGLT2 Inhibitors.
    Heath R; Johnsen H; Strain WD; Evans M
    Diabetes Ther; 2022 Feb; 13(2):241-250. PubMed ID: 35084695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lessons from a pre-specified meta-analysis of sodium-glucose cotransporter-2 (SGLT2) inhibitors in heart failure: Time for new clinical recommendations.
    Kotit S
    Glob Cardiol Sci Pract; 2023 May; 2023(2):e202314. PubMed ID: 37351098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium-glucose co-transporter 2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an updated systematic review and meta-analysis.
    Wang Y; Gao T; Meng C; Li S; Bi L; Geng Y; Zhang P
    Eur J Med Res; 2022 Dec; 27(1):314. PubMed ID: 36581880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Sodium-Glucose Cotransporter 2 Inhibitors for Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
    Zhou H; Peng W; Li F; Wang Y; Wang B; Ding Y; Lin Q; Zhao Y; Pan G; Wang X
    Front Cardiovasc Med; 2022; 9():875327. PubMed ID: 35600478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EMPEROR-Preserved: SGLT2 inhibitors breakthrough in the management of heart failure with preserved ejection fraction.
    Wagdy K; Nagy S
    Glob Cardiol Sci Pract; 2021 Oct; 2021(3):e202117. PubMed ID: 34805375
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost-effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction.
    Cohen LP; Isaza N; Hernandez I; Lewis GD; Ho JE; Fonarow GC; Kazi DS; Bellows BK
    JAMA Cardiol; 2023 May; 8(5):419-428. PubMed ID: 36870047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
    Zannad F; Ferreira JP; Pocock SJ; Anker SD; Butler J; Filippatos G; Brueckmann M; Ofstad AP; Pfarr E; Jamal W; Packer M
    Lancet; 2020 Sep; 396(10254):819-829. PubMed ID: 32877652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Review of Sodium-Glucose Cotransporter 2 Inhibitor's Clinical Efficacy in Heart Failure With Preserved Ejection Fraction.
    Epperson J; Athar ZM; Arshad M; Chen E
    Cureus; 2024 Apr; 16(4):e57380. PubMed ID: 38694659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium-Glucose Cotransporter-2 inhibitors are potential therapeutic agents for treatment of non-diabetic heart failure patients.
    Nakagawa Y; Kuwahara K
    J Cardiol; 2020 Aug; 76(2):123-131. PubMed ID: 32340780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
    Rao S
    Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale and Design of Prospective, Multicenter, Double-Arm Clinical Trial to Investigate the Efficacy of Tofogliflozin on Left Ventricular Diastolic Dysfunction in Patients with Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes Mellitus (TOP-HFPEF Trial).
    Ito S; Nakajima Y; Fukuda H; Izumi C; Nakazawa G; Yamashita H; Matsuhisa H; Inoko M; Toyoda S; Takiuchi S; Kataoka T; Izumiya Y; Abe Y; Sozu T; Sakata Y; Emoto M; Inoue T; Kitakaze M
    Cardiovasc Drugs Ther; 2024 May; ():. PubMed ID: 38727896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic Review of the Economic Evaluation of Sodium-Glucose Cotransporter-2 Inhibitors Used as Treatment in Patients with Heart Failure.
    Nam K; Cho DS; Kim H; Kwon B; Yoon Y; Park C; Kim ES; Youn JC; Park SK
    Clin Drug Investig; 2023 Jul; 43(7):463-474. PubMed ID: 37365452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial.
    Anker SD; Butler J; Filippatos GS; Jamal W; Salsali A; Schnee J; Kimura K; Zeller C; George J; Brueckmann M; Zannad F; Packer M;
    Eur J Heart Fail; 2019 Oct; 21(10):1279-1287. PubMed ID: 31523904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal Pharmacologic Treatment of Heart Failure With Preserved and Mildly Reduced Ejection Fraction: A Meta-analysis.
    Xiang B; Zhang R; Wu X; Zhou X
    JAMA Netw Open; 2022 Sep; 5(9):e2231963. PubMed ID: 36125813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of sodium-glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions.
    Lan NSR; Fegan PG; Yeap BB; Dwivedi G
    ESC Heart Fail; 2019 Oct; 6(5):927-935. PubMed ID: 31400090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Sodium-Glucose 2 Transporter Inhibitors in Heart Failure With Preserved Ejection Fraction: A Narrative Review.
    Maged R; Sinha M; Koneru HM; Sarwar H; Bandi VV; Tarar P; Halawa N
    Cureus; 2024 Sep; 16(9):e69623. PubMed ID: 39429273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Effect of Weight Loss Through Lifestyle Interventions in Patients With Heart Failure With Preserved Ejection Fraction-A Systematic Review and Meta-Analysis of Randomised Controlled Trials.
    Lee VYJ; Houston L; Perkovic A; Barraclough JY; Sweeting A; Yu J; Fletcher RA; Arnott C
    Heart Lung Circ; 2024 Feb; 33(2):197-208. PubMed ID: 38320881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.